BioNTech SE 4

BioNTech SE Chief People Officer Kylie Jimenez was granted options on 10,488 ordinary shares and 8,391 performance share units as equity compensation on May 12, 2026.

On May 12, 2026, BioNTech SE Chief People Officer Kylie Jimenez received a new equity compensation package consisting of an option to purchase 10,488 ordinary shares and a grant of 8,391 performance share units, both reported as acquisitions on Form 4. The stock option carries an exercise price of EUR 89.38 per share, vests in equal annual installments over four years starting on the first anniversary of the grant date, and becomes exercisable four years after the grant date, subject to performance-based and other conditions; it may be settled in ordinary shares, ADSs, and/or cash at the supervisory board’s election. The performance share units are economically equivalent to one ordinary share each and likewise vest annually over four years and become exercisable four years after the grant date, contingent on relative share price performance versus the Nasdaq Biotechnology Index and continued service. Following these awards, Jimenez holds 10,488 option-based rights and 8,391 PSU-based rights, all recorded as directly owned derivative interests, representing routine performance- and service-based long-term incentive compensation rather than open-market buying or selling.

Filing Facts

CIK

1776985

Ticker

BNTX

Form

4

Source Type

sec

Accession

0002123971-26-000004

Alert Tier

5